Clinical Trial Update: A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation [Phase 2]

View source ↗

Summary

A single-arm Phase II trial is evaluating Aipalolitovorelizumab (QL1706) with Bevacizumab and standard chemotherapy as first-line treatment for MSS/pMMR metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Aipalolitovorelizumab (QL1706) (Aipalolitovorelizumab)
• Bevacizumab (bevacizumab)
• Standard chemotherapy regimen (unspecified)

Snippet

Sponsor: Yanqiao Zhang | Conditions: Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING